PANK3 Antibody

What is PANK3 and why is it important in metabolic research?

PANK3 is a member of the pantothenate kinase family that catalyzes the first and rate-limiting step in coenzyme A (CoA) biosynthesis. It phosphorylates pantothenic acid (Vitamin B5) using ATP to form 4'-phosphopantothenate . PANK3 is the most highly expressed PANK isoform in humans and plays a critical role in regulating cellular CoA levels, which are essential for:

• Fatty acid synthesis and oxidation

• Pyruvate oxidation during the citric acid cycle

• Various metabolic pathways at the intersection of energy metabolism

Understanding PANK3 function is particularly important because the PANK family regulates intracellular CoA concentrations through expression levels and feedback inhibition by acyl-CoAs .

How does the MDA-299-62A antibody differ from previous attempts to detect PANK3?

The MDA-299-62A antibody represents a significant breakthrough because:

• Prior to its development, no commercial antibodies could reliably detect endogenous PANK3 protein

• While commercial antibodies could detect overexpressed PANK3, they failed to detect physiological levels of the protein

• Previous antibody development was challenged by the extreme homology between typical host species (mice/rabbits) and humans

• The structural similarities between PANK isozymes created additional challenges in generating isozyme-specific antibodies

MDA-299-62A was specifically validated using CRISPR PANK3 knockout and knockdown cell lines to confirm its specificity and reliability for detecting endogenous PANK3 protein .

What is the subcellular localization of PANK3 and how can this information guide experimental design?

PANK3 is overwhelmingly cytosolic in distribution, as demonstrated through subcellular fractionation experiments . This localization information is crucial for:

• Optimizing protein extraction protocols (cytosolic fraction isolation yields cleaner results)

• Designing imaging experiments for PANK3 detection

• Understanding functional differences between PANK isoforms (PANK2 is mitochondrial while PANK3 is cytosolic)

• Interpreting results from cellular studies examining PANK3 interactions with other proteins

This cytosolic localization contrasts with PANK2, which is the only mitochondria-targeted human PANK isoform .

What are the optimal Western blotting conditions for detecting endogenous PANK3 with MDA-299-62A?

Based on the optimization work done by researchers, the following protocol improvements increase specificity and reduce background when using MDA-299-62A:

Additionally, when analyzing whole cell lysates, the increased blocking time is particularly critical to reduce interference from non-specific bands .

How can researchers validate PANK3 antibody specificity in their experimental systems?

To ensure antibody specificity, researchers should implement multiple validation approaches:

• CRISPR Knockout Controls: Generate PANK3 CRISPR knockout cell lines as negative controls - the band should be absent in these samples

• shRNA-mediated Knockdown: Create doxycycline-inducible PANK3 shRNA cell lines to demonstrate reduced signal intensity with knockdown

• Recombinant Protein Control: Include purified recombinant PANK3 protein as a positive control to confirm correct molecular weight detection

• Subcellular Fractionation: Verify that the detected protein follows the expected cytosolic distribution pattern of PANK3

• Multiple Cell Lines: Test detection across several cell lines to confirm consistent molecular weight and expression patterns

What methods are available for generating PANK3 knockout or knockdown models to study its function?

Based on the research protocols, two primary approaches are recommended:

CRISPR/Cas9 Knockout System:

• Use a two-plasmid system (gRNA/Cas9/GFP and HDR/Puromycin/RFP)

• Follow transfection with puromycin selection (2 μg/mL) for one week

• Perform single-cell sorting using RFP as a marker

• Confirm knockout by Western blot using the validated MDA-299-62A antibody

Doxycycline-inducible shRNA System:

• Utilize third-generation lentivirus packaging system with HEK 293T cells

• Use plasmids encoding doxycycline-inducible shRNA with hygromycin-resistance marker and RFP

• Perform selection with 200 μg/mL hygromycin

• Induce knockdown with 2 μg/mL doxycycline for 48-72 hours

• Confirm knockdown by Western blot

How can the cellular engagement of PANK3-targeted compounds be validated using this antibody?

The MDA-299-62A antibody enables validation of small molecule binding to PANK3 through Cellular Thermal Shift Assay (CETSA):

• Express sufficient levels of PANK3 to be detectable by the antibody (may require transfection in some cell types)

• Treat cells with the compound of interest (e.g., PZ-2891 at varying concentrations)

• Subject cell lysates to thermal challenge at various temperatures

• Detect PANK3 stabilization using MDA-299-62A by Western blot

• Analyze thermal stability curves to determine binding affinity

The research demonstrated that PZ-2891 (a PANK activator) stabilized PANK3 by approximately 7°C, confirming compound binding in intact cells, with half-maximal binding at ~9 μM .

What are the considerations for analyzing PANK3 in relation to other PANK family members in disease models?

When investigating PANK3 in the context of disease models, researchers should consider:

• Compensatory Expression: PANK3 may show altered expression in models where other PANK isoforms are deleted or mutated. For example, in PKAN (pantothenate kinase-associated neurodegeneration) models with PANK2 mutations, PANK3 activity may partially compensate .

• Differential Tissue Expression: While PANK3 is broadly expressed across tissues, it shows particularly high expression in the liver .

• Subcellular Localization Differences: Unlike mitochondrial PANK2, cytosolic PANK3 may regulate different CoA pools within the cell .

• Therapeutic Targeting: PANK3 can be allosterically activated by small molecules like pantazines (e.g., PZ-2891), potentially offering therapeutic avenues for PKAN and other CoA-related disorders .

• Collateral Lethality Relationships: PANK1 (but not PANK3) is co-deleted with PTEN in some aggressive cancers, creating potential vulnerabilities that can be studied using the PANK3 antibody .

What methodological approaches can be used to study post-translational regulation of PANK3?

To investigate post-translational modifications and regulation of PANK3:

• Immunoprecipitation: MDA-299-62A can be used for immunoprecipitation of endogenous PANK3, followed by mass spectrometry to identify post-translational modifications .

• Feedback Inhibition Analysis: Since PANK3 is subject to feedback inhibition by CoA and its thioesters, researchers can design experiments to monitor PANK3 activity and protein-protein interactions under various metabolic conditions .

• Allosteric Regulation: Study how compounds like PZ-2891 engage the dimer interface to form a PANK- ATP- Mg²⁺- PZ-2891 complex that locks the opposite protomer in an active conformation refractory to acetyl-CoA inhibition .

• Transcriptional Regulation: Investigate transcription factors that regulate PANK3 expression, such as PPARγ which has been shown to associate with PPREs on the Pank3 locus .

• CRISPR-based Mutagenesis: Generate specific mutations in PANK3 at potential regulatory sites and study their impact on protein function and cellular CoA levels.

How can researchers apply the PANK3 antibody to investigate the role of PANK3 in cancer metabolism?

The MDA-299-62A antibody enables several experimental approaches to study PANK3's role in cancer metabolism:

• Expression Profiling: Analyze PANK3 protein levels across diverse cancer cell lines to identify correlations with metabolic phenotypes or cancer subtypes .

• Metabolic Dependency Studies: Use PANK3 knockout or knockdown models to evaluate cancer cell dependency on PANK3-regulated CoA biosynthesis .

• Therapeutic Targeting: Investigate whether PANK3 activation or inhibition affects cancer cell metabolism and viability, particularly in the context of the "collateral lethality" concept where PANK1 is co-deleted with PTEN in aggressive cancers .

• Metabolic Stress Response: Examine how PANK3 protein levels and localization change under various metabolic stresses relevant to the tumor microenvironment.

• Combined Metabolite and Protein Analysis: Correlate PANK3 protein levels with CoA and acyl-CoA metabolite profiles in cancer cells to elucidate its role in cancer-specific metabolic reprogramming.